Stephen S. Steele

Jun 1, 2023 | cuaj.ca | Peter Gariscsak |Gary Gray |Stephen S. Steele |Dean Elterman

Abstract INTRODUCTION: An estimated 18% of Canadians have overactive bladder (OAB), with approximately 24% of those reporting difficulty adhering to pharmacotherapy. To date, there has been no investigation into barriers facing sacral neuromodulation (SNM) as treatment for OAB in Canada. Current Canadian Urological Association members were invited to participate in an anonymous survey.